News Releases
Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference
May 14, 2021
Prometheus Biosciences Reports First Quarter 2021 Financial Results and Provides a Corporate Update
May 13, 2021
Prometheus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Mar 16, 2021
Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering
Mar 11, 2021
Prometheus Biosciences Announces Appointment of Mark Stenhouse as Chief Operating Officer
Mar 04, 2021
Prometheus Biosciences Commences Dosing in Multiple Ascending Dose (MAD) Portion of Ongoing Phase 1a Clinical Study of PRA023
Mar 03, 2021
Prometheus Biosciences Announces Appointments of Judith L. Swain, MD and Helen C. Adams, CPA to its Board of Directors
Feb 16, 2021
Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study
Dec 15, 2020
Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease
Nov 09, 2020
Prometheus Biosciences Appoints Olivier Laurent, Ph.D. as Chief Technology Officer
Sep 29, 2020
Displaying 21 - 30 of 34